Identifying genetic markers for drug resistance in a liver infection in Peru
Markers of Triclabendazole Resistant Fascioliasis in the Highlands of Peru
This study is looking at how certain genes in the Fasciola parasites might make them resistant to triclabendazole, the main medicine used to treat fascioliasis, which affects both people and animals, to help improve treatment for those infected.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Med Br Galveston NIH-funded |
| Lab location | 1 site (Galveston, United States) |
| Project ID | NIH-10447025 on NIH RePORTER |
What this research studies
This research investigates the genetic factors associated with resistance to triclabendazole, the primary treatment for fascioliasis, a significant neglected tropical disease affecting both humans and livestock. By analyzing the genomes of Fasciola parasites from various hosts, the study aims to identify specific genetic variants linked to drug resistance. The research also explores how these genetic markers can predict treatment outcomes in humans, thereby improving management strategies for infected individuals. Additionally, the project will assess how different doses of the drug affect the parasites at various life stages to better understand the mechanisms of resistance.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals infected with fascioliasis, particularly those who have shown resistance to triclabendazole treatment.
Not a fit: Patients who are not infected with fascioliasis or those who have not been treated with triclabendazole may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for fascioliasis, enhancing patient outcomes and reducing the burden of this disease.
How similar studies have performed: Previous research has shown success in identifying genetic markers for drug resistance in other parasitic infections, suggesting that this approach may yield valuable insights.
Where this research is happening
Galveston, United States
- University of Texas Med Br Galveston — Galveston, United States (Active)
Researchers
- Principal investigator: Cabada, Miguel Mauricio — University of Texas Med Br Galveston
- Study coordinator: Cabada, Miguel Mauricio
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.